Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

3.137.153.39
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup
Oncology

Progression-free survival may be a better primary outcome in trials on re-lapsed/refractory Ewing sarcoma

Posted on

Progression-free survival (PFS) may be a better primary outcome for clinical trials on re-lapsed/refractory Ewing sarcoma (RR-ES) since response does not correlate with survival outcomes in this population, according to data presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

In this study, data from 241 patients with RR-ES who were evaluable for imaging response were randomized to receive either topotecan-cyclophosphamide, irinotecan-temozolomide, gemcitabine-docetaxel (GD), or high-dose ifosfamide.

-Advertisement-
-Advertisement-

Progression-free survival and overall survival were similar for patients with partial response or complete response/partial response compared to those with stable disease. For patients with progressive disease, overall survival was inferior.

The authors concluded response does not correlate with survival outcomes in RR-ES and using partial or complete response as a marker of success and stable disease as a marker of failure may be misleading. Progression free survival is a potentially better primary outcome for clinical trials in RR-ES, the researchers concluded.

Reference

Wheatley K, et al. Correlation of response with progression-free (PFS) and overall (OS) survival in relapsed/refractory Ewing sarcoma (RR-ES): Results from the rEECur trial. Presented at: the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-